BioCardia (BCDA) to Release Quarterly Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14. On average, analysts expect BioCardia to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Price Performance

NASDAQ:BCDA opened at $1.16 on Tuesday. The company’s 50 day moving average is $1.23 and its 200-day moving average is $1.32. BioCardia has a 12 month low of $1.00 and a 12 month high of $3.20. The firm has a market cap of $12.69 million, a price-to-earnings ratio of -0.90 and a beta of 0.60.

Institutional Trading of BioCardia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers bought a new position in BioCardia in the 2nd quarter worth approximately $40,000. Geode Capital Management LLC boosted its position in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares during the period. Finally, DRW Securities LLC acquired a new stake in shares of BioCardia in the fourth quarter worth $72,000. Institutional investors and hedge funds own 20.57% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $25.00.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.